MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Twist Bioscience Corp

Chiusa

SettoreSettore sanitario

38 -2.09

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

37.47

Massimo

40.29

Metriche Chiave

By Trading Economics

Entrata

3.1M

-32M

Vendite

4M

89M

EPS

-0.53

Margine di Profitto

-35.614

Dipendenti

923

EBITDA

3M

-25M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+35.75% upside

Dividendi

By Dow Jones

Utili prossimi

1 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.4B

Apertura precedente

40.09

Chiusura precedente

38

Notizie sul Sentiment di mercato

By Acuity

50%

50%

180 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Twist Bioscience Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2025, 23:55 UTC

Azioni calde

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr 2025, 22:50 UTC

I principali Market Mover

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr 2025, 21:08 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr 2025, 21:00 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr 2025, 23:56 UTC

Discorsi di Mercato

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr 2025, 23:44 UTC

Notizie principali

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr 2025, 23:10 UTC

Discorsi di Mercato

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:57 UTC

Discorsi di Mercato

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr 2025, 22:56 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:56 UTC

Discorsi di Mercato

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr 2025, 22:43 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr 2025, 22:12 UTC

Discorsi di Mercato

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr 2025, 21:48 UTC

Notizie principali

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr 2025, 21:41 UTC

Discorsi di Mercato

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr 2025, 21:04 UTC

Notizie principali

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr 2025, 21:03 UTC

Discorsi di Mercato

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr 2025, 20:53 UTC

Utili

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr 2025, 20:52 UTC

Utili

Kaiser Aluminum Changes Inventory Acctg Methodology

Confronto tra pari

Modifica del prezzo

Twist Bioscience Corp Previsione

Obiettivo di Prezzo

By TipRanks

35.75% in crescita

Previsioni per 12 mesi

Media 52.86 USD  35.75%

Alto 62 USD

Basso 40 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Twist Bioscience Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

37.12 / 40.36Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

180 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.